Developer docs
API playgroundTry for free, no card

Search company profiles

Kailera Therapeutics

Full company profile

uuid00008fx

Namestring
Kailera Therapeutics
Legal namestring
KAILERA Therapeutics
Websiteurl
kailera.com
Company typeenum
Public
Founded yearint
2024
Descriptiontext

Kailera Therapeutics is a clinical-stage biotechnology company founded in 2024 and headquartered in Waltham, Massachusetts, developing GLP-1-based injectable and oral therapies for chronic weight management. The company's entire pipeline — four clinical-stage product candidates — was in-licensed from Jiangsu Hengrui Pharmaceuticals in May 2024, with Kailera holding exclusive development and commercialization rights outside of Greater China (China, Hong Kong, Macau, Taiwan). The portfolio includes ribupatide (KAI-9531), a once-weekly injectable GLP-1/GIP receptor dual agonist; an oral tablet formulation of ribupatide; KAI-7535, a once-daily oral small-molecule GLP-1 receptor agonist; and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon tri-agonist designed for improved liver fat reduction alongside weight loss. Over 2,500 participants have been dosed with ribupatide across Hengrui-conducted trials in China and Kailera-conducted global studies, and Phase 2 data showed 23.6% mean body weight loss at 36 weeks on the 8 mg dose versus 1.7% on placebo.

Kailera's lead program is now in three concurrent global Phase 3 trials (the KaiNETIC-1, -2, and -3 studies) at doses up to 10 mg, with topline results expected in Q1 2028 and a potential US launch targeted for 2029. The company has assembled an unusually experienced commercial-oriented leadership bench for a pre-launch biotech, including a Chief Commercial Officer recruited from Eli Lilly's Zepbound launch team and a CFO with a track record of biotech exits (Dicerna to Novo Nordisk for $3.3B; Jnana to Otsuka for ~$1B). The CEO, Ron Renaud, previously led Cerevel Therapeutics to its acquisition by AbbVie.

Kailera generates no product revenue. The company reported a Q1 2026 net loss of $78.9M, driven primarily by $70.9M of R&D expense, and ended the quarter with $581.9M in cash expected to fund operations into mid-2028. Total capital raised since founding exceeds $1.7B, comprising a $400M Series A (October 2024, Bain Capital Life Sciences-led), a $600M Series B (October 2025, Bain Capital Private Equity-led), and a $718.8M Nasdaq IPO in April 2026 that priced at $16/share, opened at $26, and was at the time the largest biotech IPO in history. Future revenue, when it begins, will come from prescription pharmaceutical sales of approved obesity therapies through traditional specialty pharmacy and pharmacy distribution channels; pricing has not yet been disclosed.

Short descriptiontext

Kailera Therapeutics is a clinical-stage biotechnology company developing injectable and oral GLP-1-based therapies for chronic weight management, with a lead candidate (ribupatide) in global Phase 3 trials and a targeted 2029 US launch.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
obesity therapeutics, GLP-1 receptor agonists, metabolic disease drugs, peptide drug development, clinical-stage biopharmaceutical
Industry2 codes
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Obesity Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Kailera is a clinical-stage biotech with no marketed products. The company plans to commercialize its obesity drug pipeline, with lead candidate ribupatide potentially launching in the US by 2029. Revenue will come from product sales of prescription obesity treatments.

kailera.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Kailera Therapeutics is a clinical-stage biotechnology company developing a diversified pipeline of GLP-1-based injectable and oral therapies for chronic weight management in adults with obesity and overweight conditions. Its lead product candidate ribupatide (KAI-9531) is a once-weekly injectable GLP-1/GIP receptor dual agonist in global Phase 3 development, supported by an oral ribupatide tablet, an oral small molecule GLP-1 agonist (KAI-7535), and an injectable GLP-1/GIP/glucagon tri-agonist (KAI-4729). All candidates were in-licensed from Jiangsu Hengrui Pharmaceuticals, with Kailera holding exclusive development and commercialization rights outside of Greater China.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 23.6% mean body weight loss at 36 weeks (Phase 2, 8mg dose) vs 1.7% for placebo
+4 more records
Product overview1 text field

Kailera Therapeutics is a clinical-stage biotechnology company developing a diversified pipeline of four clinical-stage GLP-1-based product candidates for obesity treatment. The company's portfolio includes ribupatide (KAI-9531), a once-weekly injectable GLP-1/GIP receptor dual agonist currently in global Phase 3 trials; an oral tablet formulation of ribupatide; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, a once-weekly injectable triple agonist. All product candidates were in-licensed from Jiangsu Hengrui Pharmaceuticals, with Kailera holding exclusive rights outside China, Hong Kong, Macau, and Taiwan. The company has no marketed products and is focused exclusively on advancing clinical development through Phase 3 trials.

Product and service4 records
1Ribupatide (KAI-9531)
CategoryInjectable obesity therapeutics
Description

A once-weekly injectable GLP-1/GIP receptor dual agonist peptide in clinical development for the treatment of obesity and overweight conditions, currently in global Phase 3 trials (KaiNETIC-1, KaiNETIC-2, KaiNETIC-3). Over 2,500 clinical trial participants have been dosed across multiple late-stage trials in China and global studies, with 23.6% mean body weight loss demonstrated in Phase 2 trials at the 8mg dose at 36 weeks. Designed with modified potency on GLP-1 and GIP receptors and longer half-life than leading obesity medications, providing improved exposure through the full weekly dosing period.

2Oral Ribupatide
CategoryOral obesity therapeutics
Description

A once-daily oral tablet formulation of ribupatide (GLP-1/GIP receptor dual agonist) in clinical development for obesity treatment, with potential for compelling weight loss and highly differentiated tolerability among oral obesity medicines. Up to 12.1% mean weight loss was demonstrated at 26 weeks in Phase 2. Designed to address patient preference for non-injectable therapies and the market gap for oral GLP-1 obesity treatments with compelling efficacy.

3KAI-7535
CategoryOral obesity therapeutics
Description

A once-daily oral small molecule GLP-1 receptor agonist in clinical development for the treatment of obesity, with potential to offer competitive weight loss and tolerability profile compared to other oral GLP-1 therapies. Leverages small-molecule chemistry rather than peptide technology, distinguishing it from injectable and oral peptide competitors in the pipeline.

4KAI-4729
CategoryInjectable obesity therapeutics
Description

A once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist in clinical development for obesity treatment, with potential for compelling weight loss, improved liver fat reduction, and a differentiated tolerability profile. The glucagon receptor addition enables liver fat reduction benefit beyond what dual agonists provide. Designed to address severe obesity cases and patients with metabolic comorbidities.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Jiangsu Hengrui Pharmaceuticals (Hengrui)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-01
Description

Strategic collaboration for obesity drug development. Kailera holds exclusive rights to development and commercialization of product candidates outside of China, Hong Kong, Macau, and Taiwan. Hengrui retains Greater China rights and conducts clinical trials in China that provide data informing Kailera's global development plans. Kailera in-licensed four GLP-1 obesity assets including ribupatide (KAI-9531/HRS9531), KAI-7535, and KAI-4729.

kailera.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Develops survodutide (a GLP-1/glucagon dual agonist) in partnership with Boehringer Ingelheim. Comparable mechanism to KAI-4729 and overlapping obesity clinical-stage profile.

TypeDirect peer
Description

Clinical-stage biotech developing VK2735 (injectable and oral GLP-1/GIP dual agonist) for obesity, with a directly comparable mechanism and clinical-stage profile. One of the most frequently cited direct comparables to ribupatide.

TypeBroad incumbent
Description

Develops and markets Zepbound (tirzepatide) for obesity and Mounjaro, the current GLP-1/GIP dual-agonist market leader that ribupatide is designed to compete against. Kailera's ex-Zepbound brand leader (Jamie Coleman) now leads Kailera's commercial build-out.

TypeBroad incumbent
Description

Advancing CT-388 (GLP-1/GIP dual agonist) and CT-996 (oral GLP-1) acquired via the Carmot deal. Large incumbent with R&D and commercial resources to compete in obesity across injectable and oral modalities.

TypeDirect peer
Description

Clinical-stage company developing GSBR-1290, an oral GLP-1 receptor agonist for obesity. Direct competitor in the oral GLP-1 segment where Kailera's oral ribupatide and KAI-7535 also compete.

TypeBroad incumbent
Description

Sells Wegovy (semaglutide) and Ozempic, the foundational GLP-1 obesity and diabetes franchises. The dominant incumbent in the GLP-1 category and the primary competitive reference point for any new obesity entrant.

TypeEmerging player
Description

Clinical-stage company with oral obesity candidates including TERN-601 (oral GLP-1). Competes with Kailera's oral ribupatide and KAI-7535 in the oral GLP-1 segment.

TypeDirect peer
Description

Clinical-stage biotech developing pemvidutide, a GLP-1/glucagon dual agonist for obesity. Comparable to Kailera's KAI-4729 triple-agonist strategy and competing in late-stage obesity trials.

TypeRegional player
Description

China-based biotech developing mazdutide (a GLP-1/glucagon dual agonist) in partnership with Eli Lilly. Holds China rights analogous to Hengrui's position versus Kailera and represents a regional competitor in the same mechanism class.

TypeEmerging player
Description

Emerging clinical-stage obesity biotech developing oral and injectable peptide therapies. Represents a newer entrant in the same clinical-stage obesity category as Kailera, often referenced as a peer comparator.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kailera Therapeutics

Obesity Therapeuticskailera.com

Kailera Therapeutics is a clinical-stage biotechnology company developing injectable and oral GLP-1-based therapies for chronic weight management, with a lead candidate (ribupatide) in global Phase 3 trials and a targeted 2029 US launch.

What Kailera Therapeutics does

Kailera Therapeutics is a clinical-stage biotechnology company founded in 2024 and headquartered in Waltham, Massachusetts, developing GLP-1-based injectable and oral therapies for chronic weight management. The company's entire pipeline — four clinical-stage product candidates — was in-licensed from Jiangsu Hengrui Pharmaceuticals in May 2024, with Kailera holding exclusive development and commercialization rights outside of Greater China (China, Hong Kong, Macau, Taiwan). The portfolio includes ribupatide (KAI-9531), a once-weekly injectable GLP-1/GIP receptor dual agonist; an oral tablet formulation of ribupatide; KAI-7535, a once-daily oral small-molecule GLP-1 receptor agonist; and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon tri-agonist designed for improved liver fat reduction alongside weight loss. Over 2,500 participants have been dosed with ribupatide across Hengrui-conducted trials in China and Kailera-conducted global studies, and Phase 2 data showed 23.6% mean body weight loss at 36 weeks on the 8 mg dose versus 1.7% on placebo.

Kailera's lead program is now in three concurrent global Phase 3 trials (the KaiNETIC-1, -2, and -3 studies) at doses up to 10 mg, with topline results expected in Q1 2028 and a potential US launch targeted for 2029. The company has assembled an unusually experienced commercial-oriented leadership bench for a pre-launch biotech, including a Chief Commercial Officer recruited from Eli Lilly's Zepbound launch team and a CFO with a track record of biotech exits (Dicerna to Novo Nordisk for $3.3B; Jnana to Otsuka for ~$1B). The CEO, Ron Renaud, previously led Cerevel Therapeutics to its acquisition by AbbVie.

Kailera generates no product revenue. The company reported a Q1 2026 net loss of $78.9M, driven primarily by $70.9M of R&D expense, and ended the quarter with $581.9M in cash expected to fund operations into mid-2028. Total capital raised since founding exceeds $1.7B, comprising a $400M Series A (October 2024, Bain Capital Life Sciences-led), a $600M Series B (October 2025, Bain Capital Private Equity-led), and a $718.8M Nasdaq IPO in April 2026 that priced at $16/share, opened at $26, and was at the time the largest biotech IPO in history. Future revenue, when it begins, will come from prescription pharmaceutical sales of approved obesity therapies through traditional specialty pharmacy and pharmacy distribution channels; pricing has not yet been disclosed.

Kailera Therapeutics firmographics

Firmographics
Name
Kailera Therapeutics
Legal name
KAILERA Therapeutics
Website
https://kailera.com
Company type
Public
Founded year
2024
Operating status
Operating
Headcount range
101–250 employees
Short description
Kailera Therapeutics is a clinical-stage biotechnology company developing injectable and oral GLP-1-based therapies for chronic weight management, with a lead candidate (ribupatide) in global Phase 3 trials and a targeted 2029 US launch.
Ownership category
akta.pro rank

Kailera Therapeutics industry classification

Industry
Product category
Obesity Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Obesity therapeutics
  • GLP-1 receptor agonists
  • Metabolic disease drugs
  • Peptide drug development
  • Clinical-stage biopharmaceutical

Where Kailera Therapeutics is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Kailera Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Kailera is a clinical-stage biotech with no marketed products. The company plans to commercialize its obesity drug pipeline, with lead candidate ribupatide potentially launching in the US by 2029. Revenue will come from product sales of prescription obesity treatments.

Go-to-market motion1 record

Marketing channels4 records

Kailera Therapeutics product offering

Product offering

Core offering

Kailera Therapeutics is a clinical-stage biotechnology company developing a diversified pipeline of GLP-1-based injectable and oral therapies for chronic weight management in adults with obesity and overweight conditions. Its lead product candidate ribupatide (KAI-9531) is a once-weekly injectable GLP-1/GIP receptor dual agonist in global Phase 3 development, supported by an oral ribupatide tablet, an oral small molecule GLP-1 agonist (KAI-7535), and an injectable GLP-1/GIP/glucagon tri-agonist (KAI-4729). All candidates were in-licensed from Jiangsu Hengrui Pharmaceuticals, with Kailera holding exclusive development and commercialization rights outside of Greater China.

Product overview

Kailera Therapeutics is a clinical-stage biotechnology company developing a diversified pipeline of four clinical-stage GLP-1-based product candidates for obesity treatment. The company's portfolio includes ribupatide (KAI-9531), a once-weekly injectable GLP-1/GIP receptor dual agonist currently in global Phase 3 trials; an oral tablet formulation of ribupatide; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, a once-weekly injectable triple agonist. All product candidates were in-licensed from Jiangsu Hengrui Pharmaceuticals, with Kailera holding exclusive rights outside China, Hong Kong, Macau, and Taiwan. The company has no marketed products and is focused exclusively on advancing clinical development through Phase 3 trials.

Differentiator

Problem solved

Functional benefit

Products and services

  • Ribupatide (KAI-9531) A once-weekly injectable GLP-1/GIP receptor dual agonist peptide in clinical development for the treatment of obesity and overweight conditions, currently in global Phase 3 trials (KaiNETIC-1, KaiNETIC-2, KaiNETIC-3). Over 2,500 clinical trial participants have been dosed across multiple late-stage trials in China and global studies, with 23.6% mean body weight loss demonstrated in Phase 2 trials at the 8mg dose at 36 weeks. Designed with modified potency on GLP-1 and GIP receptors and longer half-life than leading obesity medications, providing improved exposure through the full weekly dosing period.
  • Oral Ribupatide A once-daily oral tablet formulation of ribupatide (GLP-1/GIP receptor dual agonist) in clinical development for obesity treatment, with potential for compelling weight loss and highly differentiated tolerability among oral obesity medicines. Up to 12.1% mean weight loss was demonstrated at 26 weeks in Phase 2. Designed to address patient preference for non-injectable therapies and the market gap for oral GLP-1 obesity treatments with compelling efficacy.
  • KAI-7535 A once-daily oral small molecule GLP-1 receptor agonist in clinical development for the treatment of obesity, with potential to offer competitive weight loss and tolerability profile compared to other oral GLP-1 therapies. Leverages small-molecule chemistry rather than peptide technology, distinguishing it from injectable and oral peptide competitors in the pipeline.
  • KAI-4729 A once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist in clinical development for obesity treatment, with potential for compelling weight loss, improved liver fat reduction, and a differentiated tolerability profile. The glucagon receptor addition enables liver fat reduction benefit beyond what dual agonists provide. Designed to address severe obesity cases and patients with metabolic comorbidities.

Quantifiable outcome

  • 23.6% mean body weight loss at 36 weeks (Phase 2, 8mg dose) vs 1.7% for placebo
  • +4 more outcomes

Companies that use Kailera Therapeutics

Customer profile

Segments2 records

Ideal customer profiles3 records

Kailera Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Kailera Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Jiangsu Hengrui Pharmaceuticals (Hengrui)coreStrategic or Co-development Partner · 1 May 2024Strategic collaboration for obesity drug development. Kailera holds exclusive rights to development and commercialization of product candidates outside of China, Hong Kong, Macau, and Taiwan. Hengrui retains Greater China rights and conducts clinical trials in China that provide data informing Kailera's global development plans. Kailera in-licensed four GLP-1 obesity assets including ribupatide (KAI-9531/HRS9531), KAI-7535, and KAI-4729.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Kailera Therapeutics competitors and assessment

Company assessment

Emerging players

  • Zealand Pharma: Develops survodutide (a GLP-1/glucagon dual agonist) in partnership with Boehringer Ingelheim. Comparable mechanism to KAI-4729 and overlapping obesity clinical-stage profile.
  • Terns Pharmaceuticals: Clinical-stage company with oral obesity candidates including TERN-601 (oral GLP-1). Competes with Kailera's oral ribupatide and KAI-7535 in the oral GLP-1 segment.
  • Metsera: Emerging clinical-stage obesity biotech developing oral and injectable peptide therapies. Represents a newer entrant in the same clinical-stage obesity category as Kailera, often referenced as a peer comparator.

Direct peers

  • Viking Therapeutics: Clinical-stage biotech developing VK2735 (injectable and oral GLP-1/GIP dual agonist) for obesity, with a directly comparable mechanism and clinical-stage profile. One of the most frequently cited direct comparables to ribupatide.
  • Structure Therapeutics: Clinical-stage company developing GSBR-1290, an oral GLP-1 receptor agonist for obesity. Direct competitor in the oral GLP-1 segment where Kailera's oral ribupatide and KAI-7535 also compete.
  • Altimmune: Clinical-stage biotech developing pemvidutide, a GLP-1/glucagon dual agonist for obesity. Comparable to Kailera's KAI-4729 triple-agonist strategy and competing in late-stage obesity trials.

Broad incumbents

  • Eli Lilly: Develops and markets Zepbound (tirzepatide) for obesity and Mounjaro, the current GLP-1/GIP dual-agonist market leader that ribupatide is designed to compete against. Kailera's ex-Zepbound brand leader (Jamie Coleman) now leads Kailera's commercial build-out.
  • Roche: Advancing CT-388 (GLP-1/GIP dual agonist) and CT-996 (oral GLP-1) acquired via the Carmot deal. Large incumbent with R&D and commercial resources to compete in obesity across injectable and oral modalities.
  • Novo Nordisk: Sells Wegovy (semaglutide) and Ozempic, the foundational GLP-1 obesity and diabetes franchises. The dominant incumbent in the GLP-1 category and the primary competitive reference point for any new obesity entrant.

Regional players

  • Innovent Biologics: China-based biotech developing mazdutide (a GLP-1/glucagon dual agonist) in partnership with Eli Lilly. Holds China rights analogous to Hengrui's position versus Kailera and represents a regional competitor in the same mechanism class.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Kailera Therapeutics social profiles

Digital presence

Kailera Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kailera Therapeutics leadership team

Management profile

Number of profiles

Profiles7 records

Kailera Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kailera Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kailera Therapeutics

What does Kailera Therapeutics do?

Kailera Therapeutics is a clinical-stage biotechnology company developing a diversified pipeline of GLP-1-based injectable and oral therapies for chronic weight management in adults with obesity and overweight conditions. Its lead product candidate ribupatide (KAI-9531) is a once-weekly injectable GLP-1/GIP receptor dual agonist in global Phase 3 development, supported by an oral ribupatide tablet, an oral small molecule GLP-1 agonist (KAI-7535), and an injectable GLP-1/GIP/glucagon tri-agonist (KAI-4729). All candidates were in-licensed from Jiangsu Hengrui Pharmaceuticals, with Kailera holding exclusive development and commercialization rights outside of Greater China.

Is Kailera Therapeutics a public or private company?

Kailera Therapeutics is a public company. It is classified as public and is currently operating.

When was Kailera Therapeutics founded?

Kailera Therapeutics was founded in 2024. It employs 101 to 250 people.

Where is Kailera Therapeutics based?

Kailera Therapeutics is headquartered in Waltham, United States, in the North America region.

How does Kailera Therapeutics make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Kailera Therapeutics's main competitors?

Emerging players on record are Zealand Pharma, Terns Pharmaceuticals and Metsera. Direct peers are Viking Therapeutics, Structure Therapeutics and Altimmune. Broad incumbents are Eli Lilly, Roche and Novo Nordisk. Innovent Biologics is listed as a regional player.

Does Kailera Therapeutics have an API?

No public API is recorded for Kailera Therapeutics.

What industry is Kailera Therapeutics in?

Kailera Therapeutics's product category is Obesity Therapeutics. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyKailera to showcase obesity drug research at ObesityWeek 2026Kailera Therapeutics will present clinical and real-world research at ObesityWeek 2026 in Washington, D.C., including Phase 3 KaiNETIC-1, -2, and -3 trials. The company also plans to initiate global Phase 3 trials of ribupatide in the first half of 2027.American Banking and Market News40,739 Kailera Therapeutics, Inc. $KLRA Shares Acquired by Alps Advisors Inc.Alps Advisors increased its stake in Kailera Therapeutics by 31.1% in Q3, buying 40,739 shares to hold 171,739, valued at $1.96 million. Other hedge funds also acquired new positions, and the stock opened at $14.24. Analysts rate the stock a Moderate Buy with a $43 target.The National Law ReviewBiotech is One of the Few Sectors Where IPO Still Works as FinancBiotech IPOs remain viable as investors diversify from AI-heavy portfolios, with Kailera and Avalyn exceeding funding targets. Specialist capital is flowing into obesity, oncology, and RNA therapeutics, while M&A provides a backstop. The outlook for 2027 is selective, with companies needing differentiated science and credible sponsors.Seeking AlphaKailera Therapeutics reports Q3 results (KLRA:NASDAQ)Kailera Therapeutics reported a Q3 net loss of $95.7 million, up from $39.6 million in the same period of 2025. The company's stock is held due to the need for progress on its weight-loss differentiation.Business & FinancialKailera Therapeutics To Participate In November Investor ConferencesKailera Therapeutics will present at three investor conferences in November and December 2026, including Stifel, Jefferies, and Evercore. The company's lead product, ribupatide injection, is in global Phase 3 trials, and it is advancing oral formulations and a tri-agonist candidate.Stock TitanKailera Therapeutics to Join 3 Investor ConferencesKailera Therapeutics announced that CEO Ron Renaud and management will present at three investor conferences in November 2026, including Stifel, Jefferies, and Evercore. The company highlighted its lead product ribupatide injection in global Phase 3 trials and an oral formulation in development.FinancialContent Business PageArticles from Kailera Therapeutics, Inc.Kailera Therapeutics priced its initial public offering of 39,062,500 shares at $16.00 per share, with gross proceeds expected at $625 million. The stock will begin trading on Nasdaq on April 17, 2026, and the offering is expected to close on April 20, 2026.American Banking and Market NewsKailera Therapeutics, Inc. (NASDAQ:KLRA) Stock Now Rated “Moderate Buy” by Sell-Side AnalystsKailera Therapeutics shares received a consensus "Moderate Buy" rating from eight analysts, with an average price objective of $42.75. The company reported a loss of $1.09 per share for the quarter, missing the consensus estimate. Institutional investors have recently acquired new stakes in the stock.Simply Wall StCompanies Like Kailera Therapeutics (NASDAQ:KLRA) Are In A Position To Invest In GrowthKailera Therapeutics reported a cash burn of $224m in the last year, giving it a cash runway of about 4.1 years as of June 2026. Its cash burn increased 45% year-over-year, and the burn is about 13% of its $1.7b market cap, suggesting it could raise cash without much trouble.Longevity.TechnologyKailera’s obesity trials are full, results due 2028Kailera Therapeutics completed enrollment in its three Phase 3 trials of ribupatide, a weekly obesity injection, with about 4,900 participants. The head-to-head trial against semaglutide is expected to show results in mid-2028. The company also plans global Phase 3 trials in obesity in the first half of 2027.